Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.
A medicine company's partner shared good test results showing their cancer drug worked better than a competitor's drug in helping patients. When a drug does well in testing, it's a sign the company might be on track to eventually sell it and make money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.